Pharmacological effects of HMG CoA reductase inhibitors other than lipoprotein modulation

Journal of Clinical Pharmacology

Volumn 39, Issue 2, 1999, Pages 111-118

  White, C Michael ^a,b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Vet Aff Connecticut Hlthcare S   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BLOOD CLOTTING FACTOR; CERIVASTATIN; DOLICHOL; FIBRINOGEN; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOPRENOID; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL; UBIQUINONE;

ATHEROSCLEROSIS; BLOOD CLOTTING TIME; CELL PROLIFERATION; CLINICAL TRIAL; DRUG EFFECT; ENDOTHELIUM; FIBRINOLYSIS; HEART TRANSPLANTATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; ILEUM BYPASS; IMMUNOMODULATION; NATURAL KILLER CELL; NONHUMAN; REVIEW; THROMBOCYTE; VASCULAR SMOOTH MUSCLE; VASODILATATION;

ANIMALS; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MUSCLE, SMOOTH, VASCULAR; VASODILATION;

EID: 0032903586     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912709922007642     Document Type: Review

References (69)

1. Lovastatin-Pravastatin Study Group: A multicenter trial of lovastatin and pravastatin in the treatment of hypercholesterolemia. Am J Cardiol 1993;71:810-815.
2. Simvastatin-Pravastatin Study Group: Comparison of the efficacy, safety, and tolerability of simvastatin and pravastatin for hypercholesterolemia. Am J Cardiol 1993;71:1408-1414.
3. Andrade SE, Walker AM, Gottlieb LK, et al: Discontinuation of antihyperlididemic drugs: do rates reported in clinical trials reflect rates in primary care settings? N Engl J Med 1995;332:1125-1131.
4. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-1389.
5. Shepherd J, Cobbe SM, Ford SM, et al for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
6. Sacks FM, Pfeffer MA, Moye LA, et al for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996;335:1001-1009.
7. Blankenhorn DH, Azen Sp, Kramsch DM, et al: Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 1993;119:969-976.
8. Waters D, Higginson L, Gladstone P, et al: Effects of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 1994;89:959-968.
9. MAAS Investigators: Effect of simvastatin on coronary atheroma: the Multicentre Anti-Atheroma Study (MAAS). Lancet 1994;344: 633-638.
10. White CM, Chow MSS : A review of HMG CoA reductase inhibitors. US Pharmacist 1998;23:HS19-HS28.
11. Buchwald H, Campos CT, Boen JR, Nguyen PA, Williams SE: Disease free intervals after partial ileal bypass in patients with coronary heart disease and hypercholesterolemia: report from the Program on the Surgical Control of the Hyperlipidemias (POSCH). J Am Coll Cardiol 1995;26:351-357.
12. Vaugn CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996;348:1079-1082.
13. Zeiher AM: Endothelial vasodilator dysfunction: pathogenetic link to myocardial ischemia or epiphenomenon. Lancet 1996;348:S10-S12.
14. Anderson TJ, Uehdata A, Gerhard MD: Close relationship of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995;26:1235-1239.
15. Sorenson KE, Celemajer DS, Georgakopoulos D, Hatcher G, Betteridge DJ, Deanfield JE: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to the liporotein(a) level. J Clin Invest 1994;341:1496-1502.
16. Meredith IT, Yeung AC, Weidinger FF, et al: Role of impaired endothelium-dependent vasodilation in ischemic manifestations of coronary artery disease. Circulation 1993;83:391-401.
17. Mancini GB, Henry GC, Macaya C, et al: Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease: the TREND (Trial on Reversing Endothelial Dysfunction) study. Circulation 1996;94:258-265.
18. Rajagopalan S, Harrison DG: Reversing endothelial dysfunction with ace inhibitors: a new TREND? Circulation 1996;94:240-243.
19. Leung WH, Lau CP, Wong CK: Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993;341:1496-1499.
20. Hayoz D, Weber R, Rutschmann B, et al: Postischemic blood flow response in hypercholesterolemic patients. Hypertension 1995;26:497-502.
21. Eichstadt HW, Eskotter H, Hoffman I, Amthauer HW, Weidner G: Improvement of myocardial perfusion by short-term fluvastatin therapy in coronary artery disease. Am J Cardiol 1995;76:122A-125A.
22. Egashira K, Hirooka Y, Kai H, et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 1994;89:2519-2524.
23. Treasure CB, Klein JL, Weintraub WS, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995;332:481-487.
24. Downs JR, Clearfield M, Weis S, for the AFCAPS/TexCAPS Study Group: Air Force and Texas Coronary Atherosclerosis Prevention Study. Primary prevention of acute coronary artery events with lovastatin in men and women with average cholesterol levels. JAMA 1998;279:1615-22
25. Corsini A, Raiteri M, Soma MR, Bernini F, Fumagalli R, Paoletti R: Pathogenesis of atherosclerosis and the role of 3-hydroxy-3methylglutaryl coenzyme A reductase inhibitors. Am J Cardiol 1995;76:21A-28A.
26. Soma MR, Parolini C, Donetti E, Fumagalli R, Paoletti R: Inhibition of isoprenod biosynthesis and arterial smooth-muscle cell proliferation. J Cardiovasc Pharmacol 1995;25(Suppl. 4):S20-S24.
27. Raiteri M, Arnaboldi L, McGeady P, et al: Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther 1997;281:1144-1153.
28. Negre-Aminou P, van Vliet AK, van Erck M, van Thiel GC, van Leeuwen RE, Cohen LH: Inhibition of proliferation of human smooth muscle cells by various HMG-CoA reductase inhibitors: comparison with other human cell types. Biochem et Biophysica Acta 1997;1345:259.
29. Ross R: The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993;362:801-809.
30. Clowes AW, Clowes MM, Fingerle J: Regulation of smooth muscle cell growth in an injured artery. J Cardiovasc Pharmacol 1989;14(Suppl.):S12-S15.
31. Schwartz SM, Campbell GR, Campbell JH: Replication of smooth muscle cells in vascular disease. Circ Res 1986;58:427-444.
32. Weissberg PL, Clesham GJ, Bennet MR: Is smooth muscle cell proliferation beneficial? Lancet 1996;347:305-307.
33. O'Brien ER, Alpers CF, Stewart DK, et al: Proliferation in primary and restenotic coronary arthrectomy tissue: implications for anti-proliferative therapy. Circ Res 1993;73:323-331.
34. Strauss BH, Umans VA, van Suylen RJ, et al: Directional arthrectomy for treatment of restenosis within coronary stents: clinical, angiographic and histologic results. J Am Coll Cardiol 1992;20:1465-1473.
35. van der Wal AC, van der Loos CM, Das PK: Site of intimai rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994;89:36-44.
36. Libby P: Molecular basis of acute coronary syndromes. Circulation 1995;91:2844-2850.
37. Brown DL, Hibbs MS, Kearny M, Loushin C, Isner JM: Identification of a 92-kD gelatinase in human coronary atherosclerotic lesions : association of active enzyme synthesis in unstable angina. Circulation 1995;91:2125-2131.
38. Shiomi M, Ito T, Tsukada T, et al: Reduction of serum cholesterol levels alters lesional composition of atherosclerotic plaques: effect of pravastatin sodium on atherosclerosis in mature WHHL rabbits. Arteriosclerosis Thrombosis & Vascular Biology 1995;15:1938-1944.
39. Bauer KA: Hemostasis and thrombosis. In, Robinson SH, Reich PR (eds.): Hematology: Pathophysiologic Basis for Clinical Practice. Boston: Little, Brown, 1993;391-442.
40. Lacoste L, Lam JYT, Hung J, Letchacovski G, Solymoss CB, Waters D: Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction. Circulation 1995;92:3172-3177.
41. Lacoste L, Lam JYT: Comparative effect of pravastatin and simvastatin on platelet thrombus formation in hypercholesterolemic coronary patients (abstract). J Am Coll Cardiol 1996;413A:1045-19.
42. Aoki I, Aoki N, Kawano K, et al: Platelet-dependent thrombin generation in patients with hyperlipidemia. J AM Coll Cardiol 1997;30:91-96.
43. Berkow R: Laboratory medicine. In, The Merck Manual, 16th ed. Rahway, NJ: Merck Research Laboratories, 1992;2573-2696.
44. Barasch E, Benderly M, Graff E, et al: Plasma fibrinogen levels and their correlates in 6,457 coronary heart disease patients: the Benzafibrate infarction prevention (BIP) study. J Clin Epidemiol 1995;48:757-765.
45. Rosengren A, Wilhemsen L: Fibrinogen, coronary heart disease and mortality from all causes in smokers and nonsmokers: the study of men born in 1933. J Intern Med 1996;239:499-507.
46. Aranha-Rosito GB, Tofler GH: Hemostatic factors as triggers of cardiovascular events. Cardiol Clinics 1996;14:239-250.
47. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB: Fibrinogen and risk for cardiovascular disease. JAMA 1987;258:1183-1186.
48. Meade TW, Mellows S, Brozovic M, et al: Hemostatic function and ischemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986;2:533-537.
49. Imperatore G, Rivellese AA, Riccardi G, Vaccaro O, Iovine C: Plasma fibrinogen: a new factor of the metabolic syndrome. Diabetes Care 1998;21:649-654.
50. Triboulloy C, Peltier M, Colas L, et al: Fibrinogen is an independent marker for thoracic aortic atherosclerosis. Am J Cardiol 1998;81:321-326.
51. Schoebel FC, Gradus F, Ivens K, et al: Restenosis after elective coronary balloon angioplasty in patients with end stage renal disease: a case control study using quantitative coronary angioplasty. Heart 1997;78:337-342.
52. Jeager BR, Meiser B, Nagel D, et al: Aggressive lowering of fibrinogen and cholesterol in the prevention of graft vessel disease after heart transplantation. Circulation 1997;96(Suppl. 2):154-158.
53. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N: Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996;122:225-233.
54. Farrer M, Winocour PH, Evans K, et al: Simvastatin in noninsulin dependent diabetes mellitus: effect on serum lipids, lipoproteins and haemostatic measures. Diabetes Res Clin Pract 1994;23:111-119.
55. McDowell IF, Smye M, TrinickT, et al: Simvastatin in severe hypercholesterolemia: a placebo controlled trial. Br J Clin Pharmacol 1991;31:340-343.
56. Wierzbicki AS, Lumb PJ, Semra YK, Crook MA: Effect of atorvastatin on plasma fibrinogen. Lancet 1998;351:569-570.
57. Bakker-Arkema RG, Davidson DH, Goldstein RJ: Efficacy and safety of a new HMG CoA-reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA 1996;275:128-133.
58. Grey AB, Stapelton JP, Evans MC, Reid IR: The effect of the antiestrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women. J Clin Endocrinol Metab 1995;80:3191-3195.
59. Beigel Y, Fuchs J, Snir M, et al: Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorheologic parameters, platelet activity, and red cell morphology. J Clin Pharmacol 1991;31:512-517.
60. Zambrana JL, Velasco F, Castro P, et al: Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibitor-1 concentrations in the hyperlipidemic heart transplant patients. Am J Cardiol 1997:80:836-840.
61. Jay Rh, Rampling MW, Betteridge DJ: Abnormalities of blood rheology in familial hypercholesterolemia: effects of treatment. Atherosclerosis 1990;85:249-256.
62. Wada H, Yoshitaka M, Kaneko T, et al: Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin. Clin Therap 1992;14:829-834.
63. Tsuda Y, Satoh K, Takahashni T, Kitadai M, et al: Effect of medication with pravastatin sodium on hemorheological parameters in patients with hyperlipoprotinemia. International Angiology 1993;12:360-364.
64. Wada H, Mori Y, Wakita Y, et al: Elevated plasma levels of vascular endothelial cell markers in patients with hypercholesterolemia. Am J Hematol 1993;44:112-116.
65. Hamsten A, Wimen B, de Faire U, et al: Increased plasma levels of rapid inhibitor of tissue plasminogen activator in young survivors of myocaridal infarction. N Engl J Med 1985;313:1557-1563.
66. Huber K, Rosc D, Resch I, et al: Circadian fluctuation of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction. Thromb Haemost 1988;60:372-376.
67. Mitropoulos KA, Armitage JM, Collins R, et al: Randomized, placebo controlled study of the effects of simvastatin on hemostatic variables, lipoproteins and free fatty acids. Eur Heart J 1997;18:235-241.
68. Katznelson S, Wilkinson AH, Kobashigawa JA, et al: The effect of pravastatin on acute rejection after kidney transplantation: a pilot study. Transplantation 1996;61:1469-1474.
69. Kobashigawa JA, Katznelson AH, Laks H, et al: Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med 1995;333:621-627.